Rome IV - Opioid-Induced Constipation (OIC)

Why use it

OIC is universally underreported by patients and underprescribed against by clinicians. Uncontrolled OIC leads to discontinuation of effective analgesia in up to 20% of patients, causes significant morbidity (fecal impaction, stercoral ulceration, overflow incontinence, haemorrhoids), and substantially impairs quality of life. Systematic application of Rome IV OIC criteria enables a positive diagnosis, distinguishes OIC from pre-existing constipation or functional constipation, and directs appropriate treatment — moving beyond standard laxatives to PAMORAs when laxative therapy fails, in accordance with current NICE, AGA, and ASCO guidelines.

About

The Rome IV criteria for Opioid-Induced Constipation (OIC) were established by the Rome Foundation Bowel Disorders Committee and published in Gastroenterology in 2016. OIC is defined as a change in bowel habits (new or worsening constipation symptoms) that develops when initiating opioid therapy, that changes when opioid dose is altered, and that worsens when opioid therapy is intensified. It is the most prevalent adverse effect of opioid therapy, occurring in 40–80% of patients receiving opioids for chronic pain, cancer-related pain, or palliative conditions. The Rome IV definition differs from the earlier Rome III definition and from generic functional constipation in two important ways: (1) OIC requires a clear temporal relationship to opioid initiation, dose change, or escalation; and (2) OIC is recognised as a pathophysiologically distinct entity — mediated primarily through peripheral mu-opioid receptor activation in the enteric nervous system rather than central effects. This distinction underpins the therapeutic rationale for peripherally-acting mu-opioid receptor antagonists (PAMORAs: methylnaltrexone, naloxegol, naldemedine) which reverse intestinal opioid receptor blockade without reversing central analgesia. OIC diagnosis requires ≥2 of the standard constipation symptom criteria (from the Rome IV functional constipation item set) to be new or significantly worsened with opioid therapy, with loose stools rarely present without laxatives and insufficient criteria for IBS. No minimum duration is specified — unlike other Rome IV diagnoses, OIC can be diagnosed as soon as the temporal relationship to opioid use is established.

When to use

• Any patient receiving opioid analgesics (short-acting or long-acting, any route) who develops new or worsening constipation symptoms
• Assessment of bowel function at opioid initiation — baseline bowel habit documentation before starting opioids allows detection of OIC when it develops
• Patients on established opioid therapy with inadequately controlled constipation despite laxative use
• Guiding escalation from standard laxatives to PAMORAs (methylnaltrexone, naloxegol, naldemedine)
• Cancer patients on opioids — OIC is near-universal in this population; proactive laxative prescription at opioid initiation is standard of care
• Palliative care patients where bowel management is a major component of symptom control
• Differentiating OIC from pre-existing functional constipation or new-onset organic constipation (e.g., colorectal malignancy)
• NOT intended to replace clinical assessment for dangerous causes of new constipation (obstruction, malignancy, metabolic) — red flag symptoms must be evaluated appropriately

Formula

Pearls & pitfalls

• The Rome IV OIC definition has no minimum duration requirement — unlike functional constipation (12 weeks over 6 months), OIC can be diagnosed as soon as the temporal relationship to opioid use is established. This facilitates earlier intervention.
• All opioids cause OIC, but the relative constipation burden differs: codeine and morphine are highly constipating; tramadol, tapentadol, and buprenorphine have a lower (but not absent) constipation risk.
• PAMORAs are specifically indicated for laxative-refractory OIC — they should not replace laxatives but rather supplement them when standard treatment fails. Laxatives remain first-line because they are cheaper, familiar, and effective in a majority of patients.
• The Rome IV criteria explicitly note that OIC is distinct from irritable bowel syndrome with constipation (IBS-C) — the absence of abdominal pain as the predominant symptom with the constipation, and the clear temporal opioid relationship, distinguishes OIC.
• Methylnaltrexone acts in the gut but does not cross the blood-brain barrier — it reverses OIC without precipitating systemic opioid withdrawal or diminishing analgesia. However, in patients with a compromised blood-brain barrier (CNS tumours, meningitis, recent intracranial surgery), systemic withdrawal effects may occur.
• Alvimopan (Entereg) is a PAMORA approved in the US for short-term use in post-operative ileus in hospitalised patients — it is NOT approved for OIC in ambulatory patients and carries a black box warning for MI risk in long-term use.
• Naloxone/oxycodone combination (Targiniq/Targinact) provides built-in OIC prophylaxis — oral naloxone blocks intestinal mu-receptors while oxycodone provides analgesia. However, very high oxycodone doses may saturate oral naloxone and OIC can still occur.
• Pre-existing constipation before opioid therapy does NOT exclude OIC — the Rome IV definition requires new or WORSENING symptoms, so patients with baseline constipation who experience a clinically meaningful deterioration after opioid initiation can receive an OIC diagnosis.
• Faecal impaction must be actively excluded in any patient on opioids presenting with constipation, especially the elderly and opioid-naive patients — perform rectal examination and consider plain abdominal film if impaction is suspected.
• Patient education at opioid initiation is critical — providing laxative prescriptions prophylactically (stimulant laxative on day 1 of opioid therapy) reduces severity of OIC and improves adherence to analgesia.

Next steps

OIC confirmed: Step 1 — Laxative optimisation: stimulant laxative (senna 15–30 mg nocte or bisacodyl 5–10 mg) ± osmotic laxative (polyethylene glycol/macrogol 17 g/day, lactulose 15–30 mL BD, or magnesium hydroxide 15–30 mL daily). Step 2 — If ≥2 laxatives at adequate doses for ≥4 weeks without satisfactory response: initiate PAMORA therapy. Step 3 — PAMORA options: methylnaltrexone 8–12 mg SC every other day (licensed for laxative-refractory OIC in palliative care); naloxegol 25 mg PO OD (licensed for non-cancer chronic pain OIC); naldemedine 0.2 mg PO OD (licensed for non-cancer and cancer OIC). Step 4 — Continue opioid analgesia — PAMORAs do not reverse central analgesia. Monitor for opioid withdrawal signs (abdominal cramping, diarrhoea, anxiety) which may indicate compromise of the central blood-brain barrier. Opioid rotation: if OIC is severe and uncontrolled, consider switching to an opioid with lower constipation burden (tapentadol, buprenorphine, methadone) in consultation with a pain specialist.

Evidence

Lacy BE, Mearin F, Chang L et al. Bowel Disorders. Gastroenterology. 2016;150(6):1393-1407.e5. PMID:27144627. Primary Rome IV reference for Opioid-Induced Constipation. Camilleri M et al. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol. 2011;106(5):835-842. PMID:21206489. Ford AC et al. Efficacy of PAMORAs in patients with OIC: systematic review and meta-analysis. BMJ. 2020;367:l6634. PMID:31806548. Chey WD et al. Naloxegol for opioid-induced constipation (KODIAC trials). N Engl J Med. 2014;370(25):2387-2396. Katakami N et al. Naldemedine for OIC in patients with cancer (COMPOSE-I and II). J Clin Oncol. 2017;35(17):1921-1928.

References

1. Lacy BE, Mearin F, Chang L et al. Bowel Disorders. Gastroenterology. 2016;150(6):1393-1407.e5. — link
2. Chey WD, Webster L, Sostek M et al. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370(25):2387-2396. — link
3. Katakami N, Harada T, Murata T et al. Randomized Phase III and Extension Studies of Naldemedine in Patients with Opioid-Induced Constipation and Cancer. J Clin Oncol. 2017;35(17):1921-1928. — link
4. Thomas J, Karver S, Cooney GA et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358(22):2332-2343. — link
5. Drossman DA (ed). Rome IV: Functional Gastrointestinal Disorders. 4th ed. Raleigh, NC: Rome Foundation; 2016. — link